Dirk Weber

Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer

Nicoletta Colombo, E. Kutarska, Meletios Α. Dimopoulos et al. · Journal of Clinical Oncology · 2012 · 123 citations

Medicine, Oncology, Pharmacology +15

Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome

Gorav Batra, Tatevik Ghukasyan Lakic, Johan Lindbäck et al. · JAMA Cardiology · 2021 · 111 citations · Full text

Medicine, Cardiology, Immunology +15

Efficient Synthesis of Empagliflozin, an Inhibitor of SGLT-2, Utilizing an AlCl₃-Promoted Silane Reduction of a β-Glycopyranoside

Xiao‐jun Wang, Li Zhang, Denis Byrne et al. · Organic Letters · 2014 · 106 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

Ullrich Graeven, B. Kremer, Th Südhoff et al. · British Journal of Cancer · 2006 · 99 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

Christian Kollmannsberger, Marcus M. Schittenhelm, Friedemann Honecker et al. · Annals of Oncology · 2006 · 94 citations · Full text

Medicine, Oncology, Pharmacology +12